SEC Form 4 · accession 0001237899-18-000016
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael S Brown
Director
Period of report
Sep 27, 2018
Accepted (ET)
Sep 28, 2018 · 4:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 27, 2018 | M | 2,000 | $273.67 | A | 2,000 | D | |
| Common StockF2 | Sep 27, 2018 | S | 389 | $390.23 | D | 1,611 | D | |
| Common StockF3 | Sep 27, 2018 | S | 601 | $391.38 | D | 1,010 | D | |
| Common StockF4 | Sep 27, 2018 | S | 410 | $392.37 | D | 600 | D | |
| Common StockF5 | Sep 27, 2018 | S | 300 | $393.49 | D | 300 | D | |
| Common Stock | Sep 27, 2018 | S | 40 | $394.43 | D | 260 | D | |
| Common StockF6 | Sep 27, 2018 | S | 260 | $395.42 | D | 0 | D | |
| Common StockF7 | holding | — | — | — | 5,000 | I | by SLAT | |
| Common Stock | holding | — | — | — | 12,349 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F8 | $273.67 | Sep 27, 2018 | M | 2,000 | D | — | Jan 2, 2024 | Common Stock | 2,000 | 10,750 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2Represents volume-weighted average price of sales of 389 shares of Company stock on September 27, 2018 at prices ranging from $390.00 to $390.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
- F3Represents volume-weighted average price of sales of 601 shares of Company stock on September 27, 2018 at prices ranging from $391.00 to $391.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
- F4Represents volume-weighted average price of sales of 410 shares of Company stock on September 27, 2018 at prices ranging from $392.00 to $392.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
- F5Represents volume-weighted average price of sales of 300 shares of Company stock on September 27, 2018 at prices ranging from $393.41 to $393.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
- F6Represents volume-weighted average price of sales of 260 shares of Company stock on September 27, 2018 at prices ranging from $395.18 to $395.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 27, 2018 at each separate price.
- F7These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- F8The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.